Back to results
US 10,947,503 B2Granted
Method for modifying T cell population
AssigneeInternational Institute of Cancer Immunology, Inc.
InventorsHaruo Sugiyama, Fumihiro Fujiki
Life of this patent
Estimating the term…
Abstract
Provided is a method for increasing the proportion of memory T cells in a T cell population, said method comprising a step of adding a modulator for the retinoid metabolic pathway and/or a modulator for the retinoic acid signaling system to the T cell population.
Claims11
A method of increasing proportion of memory T cells in a T cell population, the method comprising:
- inhibiting retinoic acid production in the T cell population by adding an inhibitor of a retinoid metabolic pathway to the T cell population,
- wherein the inhibitor is siRNA, shRNA, miRNA or antisense RNA that is capable of suppressing expression of a gene encoding retinol dehydrogenase 10;
- a nucleic acid molecule that produces the siRNA, the shRNA, the miRNA or the antisense RNA;
- a vector comprising the nucleic acid molecule;
- a compound that inhibits the action of retinol dehydrogenase 10 and has the formula (I) or a salt thereof;
- or a dominant negative mutant protein of retinol dehydrogenase 10 which is a protein capable of binding to a substrate of retinol dehydrogenase 10 and incapable of catalyzing a conversion of retinol to retinal:
- wherein R is H or CH3,
- Z is HO— or HOOC—Y—COO—, and
- Y is —CH2CH2—, —CH═CH—, or a phenylene group,
- provided that the compound having the formula (I) is not RDHI-005:
7 more elements
A method of treating cancer or infection, comprising:
- administering to a subject in need thereof an adjuvant comprising an inhibitor of a retinoid metabolic pathway,
- wherein the inhibitor is siRNA, shRNA, miRNA or antisense RNA that is capable of suppressing expression of a gene encoding retinol dehydrogenase 10;
- a nucleic acid molecule that produces the siRNA, the shRNA, the miRNA or the anti sense RNA;
- a vector comprising the nucleic acid molecule;
- a compound that inhibits the action of retinol dehydrogenase 10 and has the formula (I) or a salt thereof;
- or a dominant negative mutant protein of retinol dehydrogenase 10 which is a protein capable of binding to a substrate of retinol dehydrogenase 10 and incapable of catalyzing a conversion of retinol to retinal:
- wherein R is H or CH3,
- Z is HO— or HOOC—Y—COO—, and
- Y is —CH2CH2—, —CH═CH—, or a phenylene group,
- provided that the compound having the formula (I) is not RDHI-005:
7 more elements
An immunotherapeutic method for treating cancer, comprising:
- administering to a subject in need thereof an adjuvant comprising an inhibitor of a retinoid metabolic pathway,
- wherein the inhibitor is siRNA, shRNA, miRNA or antisense RNA that is capable of suppressing expression of a gene encoding retinol dehydrogenase 10;
- a nucleic acid molecule that produces the siRNA, the shRNA, the miRNA or the antisense RNA;
- a vector comprising the nucleic acid molecule;
- a compound that inhibits the action of retinol dehydrogenase 10 and has the formula (I) or a salt thereof;
- or a dominant negative mutant protein of retinol dehydrogenase 10 which is a protein capable of binding to a substrate of retinol dehydrogenase 10 and incapable of catalyzing a conversion of retinol to retinal:
- wherein R is H or CH3,
- Z is HO— or HOOC—Y—COO—, and
- Y is —CH2CH2—, —CH═CH—, or a phenylene group,
- provided that the compound having the formula (I) is not RDHI-005:
7 more elements
A method of potentiating immunity of a subject, comprising:
- administering to the subject an inhibitor of a retinoid metabolic pathway,
- wherein the inhibitor is siRNA, shRNA, miRNA or antisense RNA that is capable of suppressing expression of a gene encoding retinol dehydrogenase 10;
- a nucleic acid molecule that produces the siRNA, the shRNA, the miRNA or the anti sense RNA;
- a vector comprising the nucleic acid molecule;
- a compound that inhibits the action of retinol dehydrogenase 10 and has the formula (I) or a salt thereof;
- or a dominant negative mutant protein of retinol dehydrogenase 10 which is a protein capable of binding to a substrate of retinol dehydrogenase 10 and incapable of catalyzing a conversion of retinol to retinal:
- wherein R is H or CH3,
- Z is HO— or HOOC—Y—COO—, and
- Y is —CH2CH2—, —CH═CH—, or a phenylene group,
- provided that the compound having the formula (I) is not RDHI-005:
7 more elements
A method of producing a T cell population, the method comprising:
- increasing proportion of memory T cells in the T cell population by adding an inhibitor of a retinoid metabolic pathway to the T cell population,
- wherein the inhibitor is siRNA, shRNA, miRNA or antisense RNA that is capable of suppressing expression of a gene encoding retinol dehydrogenase 10;
- a nucleic acid molecule that produces the siRNA, the shRNA, the miRNA or the anti sense RNA;
- a vector comprising the nucleic acid molecule;
- a compound that inhibits the action of retinol dehydrogenase 10 and has the formula (I) or a salt thereof;
- or a dominant negative mutant protein of retinol dehydrogenase 10 which is a protein capable of binding to a substrate of retinol dehydrogenase 10 and incapable of catalyzing a conversion of retinol to retinal:
- wherein R is H or CH3,
- Z is HO— or HOOC—Y—COO—, and
- Y is —CH2CH2—, —CH═CH—, or a phenylene group.
6 more elements
A method of increasing proportion of memory T cells in a T cell population, the method comprising:
- adding an inhibitor of a retinoid metabolic pathway to the T cell population in vitro,
- wherein the inhibitor is siRNA, shRNA, miRNA or antisense RNA that is capable of suppressing expression of a gene encoding retinol dehydrogenase 10;
- a nucleic acid molecule that produces the siRNA, the shRNA, the miRNA or the antisense RNA;
- a vector comprising the nucleic acid molecule;
- a compound that inhibits the action of retinol dehydrogenase 10 and has the formula (I) or a salt thereof;
- or a dominant negative mutant protein of retinol dehydrogenase 10 which is a protein capable of binding to a substrate of retinol dehydrogenase 10 and incapable of catalyzing a conversion of retinol to retinal:
- wherein R is H or CH3,
- Z is HO— or HOOC—Y—COO—, and
- Y is —CH2CH2—, —CH═CH—, or a phenylene group.
6 more elements
Dependencies are inferred from the claim text.